Clinical Study

Emr Serano Ms201964-0001- A Multicenter, Open-Label, Dose Escalation Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of The Dna-Pk Inhibitor M3814 In Combination With Avelumab With And Without Palliative Radiotherapy In Participan

Posted Date: May 22, 2020

  • Investigator: John Morris
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal for this study is To determine a safe, tolerable, RP2D and/or the MTD of M3814 when given in combination with avelumab, as well as evaluate safety and preliminary antitumor activity of M3814 in combination with avelumab.


To Be Eligible: Must Have Advanced Or Metastatic Solid Tumor For Which No Standard Therapy Exists, Measurable Disease, Ecog 0-1, No Cardiovascular Disease Or Uncontrolled Intercurrent Illness, No Active Infection, No Previous Malignancy Within 5 Years, No Hypersensitivity To Any Of Study Drugs Or Components


Phase 1, Advanced Tumors

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.